The Pharmacological Differences in Antianginal Effects of Long-lasting Calcium Channel Blockers: Azelnidipine and Amlodipine

被引:0
|
作者
Fujisawa, Michio [1 ,2 ]
Yorikane, Ryosuke [2 ]
Matsuoka, Yuko [2 ]
Koike, Hiroyuki [2 ]
Ueno, Koichi [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Div Res & Dev, Res & Dev Planning Dept, Shinagawa Ku, Tokyo 1408710, Japan
[2] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Geriatr Pharmacol & Therapeut, Chiba, Japan
关键词
azelnidipine; amlodipine; antianginal effect; vascular affinity; rate pressure product; CORONARY-ARTERY SPASM; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; ANTAGONISTS; ANGINA; DOGS; PHARMACOKINETICS; VASOCONSTRICTION; ARTERIOGRAPHY; VASOSPASM;
D O I
10.1097/FJC.0b013e3182776c28
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined antianginal effects of azelnidipine and amlodipine in an arginine vasopressin-induced rat anginal model. Oral administration of azelnidipine or amlodipine produced long lasting inhibition of arginine vasopressin-induced ST-segment depression in electrocardiogram. The degrees of inhibition with azelnidipine at doses of 1 and 3 mg/kg were comparable to those with amlodipine at 3 and 10 mg/kg. Both drugs lowered mean blood pressure in a dose-related manner, whereas only azelnidipine decreased heart rate. Azelnidipine at 3 mg/kg and amlodipine at 10 mg/kg produced a similar decrease in the rate pressure product, an index for cardiac oxygen consumption. Their inhibitory effects on calcium-induced vascular contraction were compared in isolated porcine coronary arteries. Both drugs produced a slow-developing inhibition of calcium-induced contraction. Although their inhibitory effects were similar, the way the both drugs inhibited calcium-induced contraction differed with each other. After removing the drug from bathing solution, the inhibitory effects of azelnidipine were not blunted but were sustained for a long time, which indicates that azelnidipine has high vascular affinity. On the other hand, those of amlodipine were rapidly blunted. These results suggest that the mechanisms underlying antianginal effects of azelnidipine differ from those of amlodipine. The antianginal effect with azelnidipine may be accounted for by its high affinity to the coronary blood vessels and the heart rate slowing effect, both of which are not shared with amlodipine.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 50 条
  • [41] Long-lasting effects of relative age at school
    Page, Lionel
    Sarkar, Dipanwita
    Silva-Goncalves, Juliana
    JOURNAL OF ECONOMIC BEHAVIOR & ORGANIZATION, 2019, 168 : 166 - 195
  • [42] β-blockers and calcium channel blockers' effects on risk of stroke
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) : 147 - 147
  • [43] Potentially long-lasting effects of the pandemic on scientists
    Gao, Jian
    Yin, Yian
    Myers, Kyle R.
    Lakhani, Karim R.
    Wang, Dashun
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [44] Are the Effects of Response Inhibition on Gambling Long-Lasting?
    Verbruggen, Frederick
    Adams, Rachel C.
    van 't Wout, Felice
    Stevens, Tobias
    McLaren, Ian P. L.
    Chambers, Christopher D.
    PLOS ONE, 2013, 8 (07):
  • [45] Class differences in the effects of calcium channel blockers in the rat remnant kidney model
    Griffin, KA
    Picken, MM
    Bakris, GL
    Bidani, AK
    KIDNEY INTERNATIONAL, 1999, 55 (05) : 1849 - 1860
  • [46] Pleiotropic Effects of Calcium Channel Blockers
    Mason, R. Preston
    CURRENT HYPERTENSION REPORTS, 2012, 14 (04) : 293 - 303
  • [47] Antiatherosclerotic effects of calcium channel blockers
    Mancini, GBJ
    PROGRESS IN CARDIOVASCULAR DISEASES, 2002, 45 (01) : 1 - 20
  • [48] Pleiotropic effects of calcium channel blockers
    Shigeru Toyoda
    Masashi Sakuma
    Koichi Node
    Teruo Inoue
    Hypertension Research, 2018, 41 : 230 - 233
  • [49] Calcium channel blockers side effects
    Charfi, O.
    Zaiem, A.
    Lakhoua, G.
    Sahnoun, R.
    Daghfous, R.
    Kastalli, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 83 - 84
  • [50] Pleiotropic Effects of Calcium Channel Blockers
    R. Preston Mason
    Current Hypertension Reports, 2012, 14 : 293 - 303